Sarah Cannon Research Institute | Strategic Alliance Partners

April 07, 2023

Robert L. Coleman, MD, FACOG, FACS, discusses a subgroup analysis of the SORAYA trial, which was presented during the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, and where the field is headed in attempt to address unmet needs for this patient population.

March 31, 2023

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

March 31, 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

March 24, 2023

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.

March 24, 2023

Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.

March 17, 2023

Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.

March 17, 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.

March 14, 2023

Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.

February 21, 2023

Looking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.

February 16, 2023

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

February 14, 2023

Experts discuss the role of neoadjuvant therapy and other emerging therapies in the treatment of early-stage NSCLC.

February 14, 2023

Jaspal Singh, MD, MHS, shares insights on treatment strategies for patients with stage II-IIIA NSCLC.

February 07, 2023

With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.

February 07, 2023

David H. Harpole Jr, MD, presents a case of a former smoker diagnosed with NSCLC, and David Spigel, MD, offers his initial impressions.

February 07, 2023

An expert panel shares perspectives on how to choose the appropriate patients with non-small cell lung cancer for lung resection.

February 01, 2023

Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.

January 31, 2023

A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.

January 31, 2023

David Spigel, MD, and David H. Harpole Jr, MD, describe when adjuvant therapy is recommended in early stage NSCLC and discuss data from recent clinical trials of adjuvant therapy.

January 25, 2023

Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

January 23, 2023

Andrew McKenzie, PhD, discusses biomarkers to test for in breast and lung cancers, the value of multicancer early detection, and how biomarker testing can better direct targeted treatment across solid tumors.